This inventor holds 1 USPTO granted patent, plus 3 CIPO patents and 1 EPO patent. Top assignee: Lockheed Martin Corporation. Active years: 2000.
Company Filing History:
Years Active: 2000
Title: Christopher Charles Jones: Innovator in Pharmaceutical Compounds
Introduction
Christopher Charles Jones is a notable inventor based in the United States. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target kinase activity. His work is crucial in the fight against hyperproliferative diseases, including cancer.
Latest Patents
Jones holds patents for innovative compounds, including "Novel Imidazole Amines As Modulators Of Kinase Activity." This invention provides novel imidazole amine compounds according to Formula (I) and Formula (II), which are manufactured for the treatment of hyperproliferative diseases. Another significant patent is for "Tricyclic Azaindoles," which discloses dipyridyl-pyrrole derivative compounds and analogs. These compounds are useful in treating diseases that can be addressed through protein kinase signal transduction inhibition.
Career Highlights
Christopher Charles Jones is currently employed at Merck Patent GmbH, where he continues to innovate in the pharmaceutical sector. His work focuses on developing new compounds that can effectively treat various diseases.
Collaborations
Some of his notable coworkers include Bayard R Huck and Amanda E Sutton, who contribute to the collaborative efforts in research and development at Merck.
Conclusion
Christopher Charles Jones is a dedicated inventor whose work in pharmaceutical compounds is paving the way for new treatments for serious diseases. His innovative contributions are essential in advancing medical science and improving patient outcomes.